Candida auris Blood stream infection- a descriptive study from Qatar.
Blood stream infection
COVID-19
Candida auris
Candidemia
Fungemia
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Aug 2023
06 Aug 2023
Historique:
received:
24
03
2023
accepted:
21
07
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
6
8
2023
Statut:
epublish
Résumé
Candida auris is an emerging yeast pathogen that can cause invasive infections, particularly candidemia, in healthcare settings. Candida auris is characterized by resistance to multiple classes of antifungal drugs and high mortality. To describe the risk factors, clinical characteristics, antifungal susceptibility pattern and outcomes of Candida auris blood stream infection. We conducted a retrospective review of electronic medical records of C. auris fungemia cases in the facilities under Hamad Medical corporation, Qatar from 1/11/2018 to 31/7/2021. Demographic data, risk factors, antibiogram and 30-day outcome are described. We identified 36 patients with C. auris fungemia. Most of the patients were in intensive care unit following severe COVID-19 pneumonia and had received steroids and broad-spectrum antibiotics. Most cases were central line related. Over 90% of isolates were non-susceptible to fluconazole, while amphotericin B resistance reached 85%. Factors associated with high mortality included initial SOFA score of 9 or above and absence of source control. Our study reveals a concerning 41.6% mortality rate within 30 days of C. auris candidemia. Furthermore, the prevalence of amphotericin B resistance in Qatar exceeds what has been reported in the literature necessitating further exploration. Echinocandins retains nearly 100% susceptibility and should be prioritized as the treatment of choice. These findings emphasize the need for vigilant monitoring and appropriate management strategies to combat C. auris infections and improve patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Candida auris is an emerging yeast pathogen that can cause invasive infections, particularly candidemia, in healthcare settings. Candida auris is characterized by resistance to multiple classes of antifungal drugs and high mortality.
OBJECTIVE
OBJECTIVE
To describe the risk factors, clinical characteristics, antifungal susceptibility pattern and outcomes of Candida auris blood stream infection.
METHODS
METHODS
We conducted a retrospective review of electronic medical records of C. auris fungemia cases in the facilities under Hamad Medical corporation, Qatar from 1/11/2018 to 31/7/2021. Demographic data, risk factors, antibiogram and 30-day outcome are described.
RESULTS
RESULTS
We identified 36 patients with C. auris fungemia. Most of the patients were in intensive care unit following severe COVID-19 pneumonia and had received steroids and broad-spectrum antibiotics. Most cases were central line related. Over 90% of isolates were non-susceptible to fluconazole, while amphotericin B resistance reached 85%. Factors associated with high mortality included initial SOFA score of 9 or above and absence of source control.
CONCLUSION
CONCLUSIONS
Our study reveals a concerning 41.6% mortality rate within 30 days of C. auris candidemia. Furthermore, the prevalence of amphotericin B resistance in Qatar exceeds what has been reported in the literature necessitating further exploration. Echinocandins retains nearly 100% susceptibility and should be prioritized as the treatment of choice. These findings emphasize the need for vigilant monitoring and appropriate management strategies to combat C. auris infections and improve patient outcomes.
Identifiants
pubmed: 37544995
doi: 10.1186/s12879-023-08477-5
pii: 10.1186/s12879-023-08477-5
pmc: PMC10405369
doi:
Substances chimiques
Amphotericin B
7XU7A7DROE
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
513Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMC Infect Dis. 2021 Jan 15;21(1):77
pubmed: 33451284
Clin Infect Dis. 2017 Jan 15;64(2):134-140
pubmed: 27988485
Am J Transplant. 2017 Jan;17(1):296-299
pubmed: 28029734
Microbiologyopen. 2018 Aug;7(4):e00578
pubmed: 29345117
Microbiol Immunol. 2009 Jan;53(1):41-4
pubmed: 19161556
Open Forum Infect Dis. 2019 Jun 01;6(7):ofz262
pubmed: 31281859
Intensive Care Med. 2015 Feb;41(2):285-95
pubmed: 25510301
Pathogens. 2021 Feb 03;10(2):
pubmed: 33546137
Clin Microbiol Infect. 2023 Aug;29(8):1083.e1-1083.e7
pubmed: 37116861
PLoS One. 2018 Apr 9;13(4):e0195743
pubmed: 29630658
Antibiotics (Basel). 2020 Sep 24;9(10):
pubmed: 32987692
Am J Infect Control. 2022 Mar;50(3):277-282
pubmed: 35000801
Clin Infect Dis. 2023 Feb 8;76(3):e1436-e1443
pubmed: 36062367
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29167291
J Fungi (Basel). 2021 Jan 07;7(1):
pubmed: 33430221
J Fungi (Basel). 2021 Mar 23;7(3):
pubmed: 33807036
J Clin Microbiol. 2011 Sep;49(9):3139-42
pubmed: 21715586
Antimicrob Resist Infect Control. 2016 Oct 19;5:35
pubmed: 27777756
Med Mycol. 2021 Dec 03;59(12):1262-1266
pubmed: 34625808
Open Forum Infect Dis. 2021 Sep 07;8(12):ofab452
pubmed: 34904116
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Infection. 2018 Oct;46(5):641-650
pubmed: 29949089
J Infect. 2021 Feb;82(2):e45-e46
pubmed: 32771402
Infect Dis Ther. 2022 Jun;11(3):1149-1160
pubmed: 35404010
J Fungi (Basel). 2021 Feb 15;7(2):
pubmed: 33672021
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Arch Pathol Lab Med. 2020 Jan;144(1):107-114
pubmed: 31169997
Mycoses. 2020 May;63(5):452-460
pubmed: 32072717
Antimicrob Resist Infect Control. 2022 Mar 7;11(1):45
pubmed: 35255988
IDCases. 2020 Nov 12;23:e01007
pubmed: 33299794
J Fungi (Basel). 2019 Oct 23;5(4):
pubmed: 31652825
BMC Infect Dis. 2020 Nov 11;20(1):827
pubmed: 33176724
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Mycoses. 2018 Jul;61(7):498-505
pubmed: 29655180
Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):919-26
pubmed: 24357342
J Infect. 2016 Oct;73(4):369-74
pubmed: 27452195
Clin Microbiol Rev. 2017 Nov 15;31(1):
pubmed: 29142078
J Infect Chemother. 2019 May;25(5):341-345
pubmed: 30718191
Mycoses. 2022 Jul;65(7):683-703
pubmed: 35555921